Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2025-12-25 @ 11:10 PM
NCT ID:
NCT02644967
Pre Assignment Details:
In the Phase 2 study, all participants were assigned to a single arm and received IMO-2125 (tilsotolimod \[tilso\]) at the recommended Phase 2 dose (RP2D) of 8 mg, in combination with ipilimumab (ipi).
Recruitment Details:
The Phase 2 study was conducted at nine (9) academic cancer centers.
Study:
NCT02644967
Study Brief:
Results Section:
NCT02644967